GHIT FUND
ANNUAL REPORT
2017

Message from Chair & CEO

We are immensely proud of the robust portfolio of products with life-saving potential that we have created with our ever expanding network of partners in Japan and around the world during our first five years. As a result of this work, the global health R&D pipeline is more vibrant than ever, leveraging Japanese innovation to help realize the promise of better, more prosperous lives for hundreds of millions of people across the globe.

Thanks to the unparalleled foresight, engagement, creativity, and unwavering support of our funders, development partners, and governors, we close our first phase of operations and enter the next with unparalleled energy, optimism, and drive.

The really important work starts now, and we’re ready for it.

Kiyoshi Kurokawa, MD
Board Chair
BT Slingsby, MD, PhD, MPH
Chief Executive Officer

GHIT Leveraged Investment

USD190M

Investment Overview

FY2013-FY2017

  • USD132M
    Total Investments
  • 74
    Total Invested Partnerships
  • 49
    Active InvestmentsAs of March, 2017

Product development organizations partnering with us

  • 42
    Japan
  • 7
    Asia
  • 17
    Europe
  • 22
    North America
  • 8
    South America
  • 7
    Africa

Our Portfolio

USD 132M, FY2013-FY2017

Disease
Intervention
Development
Stage
Malaria
40.6%
Tuberculosis
12.5%
NTDs
46.9%
Drugs
70.6%
Vaccines
24.5%
Diagnostics
4.9%
Discovery
18.6%
Preclinical
39.0%
Clinical
42.4%

Our Portfolio

USD 132M, FY2013-FY2017

Disease
Malaria
40.6%
Tuberculosis
12.5%
NTDs
46.9%
Intervention
Drugs
70.6%
Vaccines
24.5%
Diagnostics
4.9%
Development
Stage
Discovery
18.6%
Preclinical
39.0%
Clinical
42.4%

Late-Stage Candidates

Eight GHIT development partnerships have conducted successful late-stage projects in Africa and South America. As a result,
and numerous promising global health innovations are now firmly within reach.

Late-Stage Candidates

Eight GHIT development partnerships have conducted successful late-stage projects in Africa and South America. As a result,
and numerous promising global health innovations are now firmly within reach.

DSM265
Disease: Malaria
Intervention: Drug
Development Stage: Phase IIa
Country: TBD
Project Detail
E1224
Disease: Chagas disease
Intervention: Drug
Development Stage: Phase IIa
Country: Bolivia
Project Detail
PZQ
Disease: Schistosomiasis
Intervention: Pediatric Drug
Development Stage and Country:
Phase IIb (Ivory Coast) /
Phase III (Kenya)
Project Detail
DAR-901
Disease: Tuberculosis
Intervention: Vaccine
Development Stage: Phase IIb
Country: Tanzania
Project Detail
BK-SE36/CpG
Disease: Malaria
Intervention: Vaccine
Development Stage: Phase Ib
Country: Burkina Faso
Project Detail
SJ733
Disease: Malaria
Intervention: Drug
Development Stage: Phase IIa
Country: TBD
Project Detail
Arne Hoel_World Bank
TB-LAM
Disease: Tuberculosis
Intervention: Diagnostic
Development Stage: Product validation
Country: South Africa
Project Detail
Abraham Ali/Imageworks-DNDi
E1224
Disease: Mycetoma
Intervention: Drug
Development Stage: Phase IIb
Country: Sudan
Project Detail

GHIT Replenishment

On June 1, 2017, we announced our replenishment with a USD 200 million commitment
from funding partners for the next five years (FY2018–FY2022).

  • USD145M
    FY2013-FY2017
  • USD200M
    FY2018-FY2022
  • Strategic Plan
    FY2018-FY2022

    Our Strategic Plan targeting the next five years (FY2018-FY2022) is comprised of four pillars: Research & Development, including two products to be approved by a stringent regulatory authority by the end of FY2022; Partnership for Delivery; Excellence through Good Governance; and Financial Strategies.

    Learn More

GHIT R&D Forum

Our inaugural R&D Forum convened on December 8, 2017, bringing together more than 80 Japanese and non-Japanese life science companies, research institutions, universities, international organizations, and nonprofit and nongovernmental organizations to engage in unprecedented, interactive peer-to-peer exchange.

Discussions highlighted the ways in which GHIT works as a global hub for Japanese and overseas institutions from all sectors involved in global health R&D, facilitating international collaboration and open innovation on product development, access, and delivery.

Event Report